BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19, is ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

This update wasn't well-received by investors, and Moderna's share price sank nearly 17%. The conventional investing wisdom is that you shouldn't "try to catch a falling knife." Moderna's stock ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research report report published on Monday,Benzinga reports. Evercore ISI currently has ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

At a 15.9x PE multiple, these earnings would justify Moderna's current share price. Biopharmaceutical companies are inherently risky investments - their products can literally kill someone or cure ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Moderna's share price plunged after the company cut its 2025 sales guidance. The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product ...